2 results
Approved WMOCompleted
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
Approved WMOPending
General- To determine the safety of OTL38 in IBD and rheumatoid arthritis patients by monitoring of vital signs during tracer infusion and evaluating possible (severe) adverse events (SAE/AEs).RA- To determine the feasibility of molecular…